See more : Nikhil Adhesives Limited (NIKHILAD.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Chemo Pharma Laboratories Limited (CHEMOPH.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chemo Pharma Laboratories Limited, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- 2seventy bio, Inc. (TSVT) Income Statement Analysis – Financial Results
- Kyowa Kirin Co., Ltd. (KYKOF) Income Statement Analysis – Financial Results
- Birla Cable Limited (BIRLACABLE.BO) Income Statement Analysis – Financial Results
- Eastern Bankshares, Inc. (EBC) Income Statement Analysis – Financial Results
- PGG Wrightson Limited (PGWFF) Income Statement Analysis – Financial Results
Chemo Pharma Laboratories Limited (CHEMOPH.BO)
Industry: Medical - Pharmaceuticals
Sector: Healthcare
About Chemo Pharma Laboratories Limited
Chemo Pharma Laboratories Ltd. is formerly a pharmaceutical company, which aims to acquire power and chemicals businesses. The company was founded on August 17, 1942 and is headquartered in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 18.38M | 2.95M | 7.89M | 5.48M | 9.97M |
| Cost of Revenue | 0.00 | 5.20K | 8.50K | 23.31K | 16.62K |
| Gross Profit | 18.38M | 2.95M | 7.88M | 5.46M | 9.95M |
| Gross Profit Ratio | 100.00% | 99.82% | 99.89% | 99.57% | 99.83% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.68M | 269.77K | 1.24M | 295.45K | 0.00 |
| Selling & Marketing | 0.00 | 35.28K | 43.53K | 33.81K | 46.25K |
| SG&A | 1.68M | 305.05K | 1.28M | 329.25K | 46.25K |
| Other Expenses | 0.00 | 2.95M | 980.00 | 6.68M | 0.00 |
| Operating Expenses | 1.95M | 2.04M | 4.24M | 1.61M | 5.01M |
| Cost & Expenses | 1.95M | 2.04M | 4.24M | 1.61M | 5.03M |
| Interest Income | 0.00 | 4.73M | 4.75M | 5.31M | 9.96M |
| Interest Expense | 0.00 | 108.30K | 0.00 | 750.00 | 0.00 |
| Depreciation & Amortization | 83.00K | 131.01K | 189.31K | 239.39K | 231.27K |
| EBITDA | 16.52M | 971.28K | 2.66M | 3.94M | 0.00 |
| EBITDA Ratio | 89.86% | 175.30% | 33.73% | 71.92% | 53.23% |
| Operating Income | 16.43M | 5.04M | 2.47M | 3.70M | 5.07M |
| Operating Income Ratio | 89.41% | 170.86% | 31.33% | 67.56% | 50.91% |
| Total Other Income/Expenses | 1.00K | -108.30K | 0.00 | -750.00 | -132.92K |
| Income Before Tax | 16.44M | 731.97K | 3.65M | 3.11M | 4.94M |
| Income Before Tax Ratio | 89.41% | 24.80% | 46.26% | 56.66% | 49.57% |
| Income Tax Expense | 4.43M | 258.93K | -1.95M | 606.26K | 789.79K |
| Net Income | 12.00M | 473.03K | 5.60M | 2.50M | 4.15M |
| Net Income Ratio | 65.30% | 16.03% | 70.98% | 45.61% | 41.65% |
| EPS | 8.00 | 0.32 | 3.73 | 1.67 | 2.77 |
| EPS Diluted | 8.00 | 0.32 | 3.73 | 1.67 | 2.77 |
| Weighted Avg Shares Out | 1.50M | 1.48M | 1.50M | 1.50M | 1.50M |
| Weighted Avg Shares Out (Dil) | 1.50M | 1.48M | 1.50M | 1.50M | 1.50M |
Source: https://incomestatements.info
Category: Stock Reports